339 related articles for article (PubMed ID: 22017376)
1. Antitumor activities of valproic acid on Epstein-Barr virus-associated T and natural killer lymphoma cells.
Iwata S; Saito T; Ito Y; Kamakura M; Gotoh K; Kawada J; Nishiyama Y; Kimura H
Cancer Sci; 2012 Feb; 103(2):375-81. PubMed ID: 22017376
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib induces apoptosis in T lymphoma cells and natural killer lymphoma cells independent of Epstein-Barr virus infection.
Iwata S; Yano S; Ito Y; Ushijima Y; Gotoh K; Kawada J; Fujiwara S; Sugimoto K; Isobe Y; Nishiyama Y; Kimura H
Int J Cancer; 2011 Nov; 129(9):2263-73. PubMed ID: 21170988
[TBL] [Abstract][Full Text] [Related]
3. mTOR inhibitors induce cell-cycle arrest and inhibit tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells.
Kawada J; Ito Y; Iwata S; Suzuki M; Kawano Y; Kanazawa T; Siddiquey MN; Kimura H
Clin Cancer Res; 2014 Nov; 20(21):5412-22. PubMed ID: 25208880
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumor effects of suberoylanilide hydroxamic acid on Epstein-Barr virus-associated T cell and natural killer cell lymphoma.
Siddiquey MN; Nakagawa H; Iwata S; Kanazawa T; Suzuki M; Imadome K; Fujiwara S; Goshima F; Murata T; Kimura H
Cancer Sci; 2014 Jun; 105(6):713-22. PubMed ID: 24712440
[TBL] [Abstract][Full Text] [Related]
5. Coexpression of CD40 and CD40 ligand in Epstein-Barr virus-infected T and NK cells and their role in cell survival.
Imadome K; Shimizu N; Arai A; Miura O; Watanabe K; Nakamura H; Nonoyama S; Yamamoto K; Fujiwara S
J Infect Dis; 2005 Oct; 192(8):1340-8. PubMed ID: 16170750
[TBL] [Abstract][Full Text] [Related]
6. Valproic acid inhibits proliferation of EB virus-infected natural killer cells.
Fujii K; Suzuki N; Yamamoto T; Suzuki D; Iwatsuki K
Hematology; 2012 May; 17(3):163-9. PubMed ID: 22664116
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological states of Epstein-Barr virus-associated T/NK-cell lymphoproliferative disorders (severe chronic active EBV infection) of children and young adults.
Suzuki K; Ohshima K; Karube K; Suzumiya J; Ohga S; Ishihara S; Tamura K; Kikuchi M
Int J Oncol; 2004 May; 24(5):1165-74. PubMed ID: 15067338
[TBL] [Abstract][Full Text] [Related]
8. T/NK cell type chronic active Epstein-Barr virus disease in adults: an underlying condition for Epstein-Barr virus-associated T/NK-cell lymphoma.
Isobe Y; Aritaka N; Setoguchi Y; Ito Y; Kimura H; Hamano Y; Sugimoto K; Komatsu N
J Clin Pathol; 2012 Mar; 65(3):278-82. PubMed ID: 22247563
[TBL] [Abstract][Full Text] [Related]
9. Combination of SAHA and bortezomib up-regulates CDKN2A and CDKN1A and induces apoptosis of Epstein-Barr virus-positive Wp-restricted Burkitt lymphoma and lymphoblastoid cell lines.
Hui KF; Leung YY; Yeung PL; Middeldorp JM; Chiang AK
Br J Haematol; 2014 Dec; 167(5):639-50. PubMed ID: 25155625
[TBL] [Abstract][Full Text] [Related]
10. Clonal origin of Epstein-Barr virus (EBV)-infected T/NK-cell subpopulations in EBV-positive T/NK-cell lymphoproliferative disorders of childhood.
Ohga S; Ishimura M; Yoshimoto G; Miyamoto T; Takada H; Tanaka T; Ohshima K; Ogawa Y; Imadome K; Abe Y; Akashi K; Hara T
J Clin Virol; 2011 May; 51(1):31-7. PubMed ID: 21377409
[TBL] [Abstract][Full Text] [Related]
11. Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression.
Feng WH; Kenney SC
Cancer Res; 2006 Sep; 66(17):8762-9. PubMed ID: 16951192
[TBL] [Abstract][Full Text] [Related]
12. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
Roychowdhury S; Baiocchi RA; Vourganti S; Bhatt D; Blaser BW; Freud AG; Chou J; Chen CS; Xiao JJ; Parthun M; Chan KK; Eisenbeis CF; Ferketich AK; Grever MR; Chen CS; Caligiuri MA
J Natl Cancer Inst; 2004 Oct; 96(19):1447-57. PubMed ID: 15467034
[TBL] [Abstract][Full Text] [Related]
13. Tofacitinib induces G1 cell-cycle arrest and inhibits tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells.
Ando S; Kawada JI; Watanabe T; Suzuki M; Sato Y; Torii Y; Asai M; Goshima F; Murata T; Shimizu N; Ito Y; Kimura H
Oncotarget; 2016 Nov; 7(47):76793-76805. PubMed ID: 27732937
[TBL] [Abstract][Full Text] [Related]
14. Proposed categorization of pathological states of EBV-associated T/natural killer-cell lymphoproliferative disorder (LPD) in children and young adults: overlap with chronic active EBV infection and infantile fulminant EBV T-LPD.
Ohshima K; Kimura H; Yoshino T; Kim CW; Ko YH; Lee SS; Peh SC; Chan JK;
Pathol Int; 2008 Apr; 58(4):209-17. PubMed ID: 18324913
[TBL] [Abstract][Full Text] [Related]
15. Valproic acid cooperates with hydralazine to augment the susceptibility of human osteosarcoma cells to Fas- and NK cell-mediated cell death.
Yamanegi K; Yamane J; Kobayashi K; Kato-Kogoe N; Ohyama H; Nakasho K; Yamada N; Hata M; Fukunaga S; Futani H; Okamura H; Terada N
Int J Oncol; 2012 Jul; 41(1):83-91. PubMed ID: 22576685
[TBL] [Abstract][Full Text] [Related]
16. Suberoylanilide hydroxamic acid induces viral lytic cycle in Epstein-Barr virus-positive epithelial malignancies and mediates enhanced cell death.
Hui KF; Chiang AK
Int J Cancer; 2010 May; 126(10):2479-89. PubMed ID: 19816947
[TBL] [Abstract][Full Text] [Related]
17. Sodium valproate in combination with ganciclovir induces lysis of EBV-infected lymphoma cells without impairing EBV-specific T-cell immunity.
Jones K; Nourse J; Corbett G; Gandhi MK
Int J Lab Hematol; 2010 Feb; 32(1 Pt 1):e169-74. PubMed ID: 19196381
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic hematopoietic stem cell transplantation for Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disease in Japan.
Sato E; Ohga S; Kuroda H; Yoshiba F; Nishimura M; Nagasawa M; Inoue M; Kawa K
Am J Hematol; 2008 Sep; 83(9):721-7. PubMed ID: 18626884
[TBL] [Abstract][Full Text] [Related]
19. NK-cell repertoire is feasible for diagnosing Epstein-Barr virus-infected NK-cell lymphoproliferative disease and evaluating the treatment effect.
Sawada A; Sato E; Koyama M; Higuchi B; Kusuki S; Kim JY; Takeshita Y; Sakata A; Sakata N; Okamura T; Yasui M; Inoue M; Kawa K
Am J Hematol; 2006 Aug; 81(8):576-81. PubMed ID: 16823820
[TBL] [Abstract][Full Text] [Related]
20. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma.
Heider U; Rademacher J; Lamottke B; Mieth M; Moebs M; von Metzler I; Assaf C; Sezer O
Eur J Haematol; 2009 Jun; 82(6):440-9. PubMed ID: 19220424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]